Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma

September 21, 2020

Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.

Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes

September 21, 2020

Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.

Ewing Sarcoma May Benefit From Regorafenib Therapy

September 20, 2020

As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.

Investigators Observe Differences in Toxicity for Sarcoma Due to Dosing

July 14, 2020

Gary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.

Evaluating the Activity of Trabectedin and Radiotherapy in Sarcoma

June 19, 2020

Alessandro Gronchi, MD, discusses a phase 2 trial of trabectedin and radiotherapy in patients with soft-tissue sarcoma.

Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPS

June 02, 2020

Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Treatment Options Evolve for Patients With Desmoid Fibromatosis

May 18, 2020

Neeta Somaiah, MD, discusses the evolution of treatment options for patients with a unique sarcoma.

FDA Approves Pomalidomide for Treatment of Kaposi Sarcoma

May 15, 2020

Pomalidomide is now FDA approved for treatment of Kaposi sarcoma under multiple indications.

Patients With Pretreated Sarcoma May Derive Benefit From Various Immunotherapy Combinations

April 15, 2020

Combination therapy strategies involving immune checkpoint inhibitors and a secondary agent have shown promise across sarcoma subtypes, according to analysis of clinical trial data that were presented at the European Society for Medical Oncology Sarcoma & GIST Symposium 2020, held in Milan, Italy.

Cabozantinib May Be a New Therapeutic Option for Ewing Sarcoma and Osteosarcoma

April 03, 2020

Cabozantinib demonstrated antitumor activity as treatment of patients with advanced Ewing sarcoma and osteosarcoma, warranting further investigation for a potential new therapeutic option for this patient population, according to findings from phase II CABONE study.